Tyrosine kinases, drugs, and Shigella flexneri dissemination

References

• Dragoi AM, Talman AM, Agaisse H. Bruton’s tyrosine kinase regulates Shigella flexneri dissemination in HT-29 intestinal cells. Infect Immun 2013; 81:598 - 607; http://dx.doi.org/10.1128/IAI.00853-12; PMID: 23230296
   PubMed Web of Science ®Google Scholar
• Sansonetti PJ. Molecular and cellular mechanisms of invasion of the intestinal barrier by enteric pathogens. The paradigm of Shigella. Folia Microbiol (Praha) 1998; 43:239 - 46; http://dx.doi.org/10.1007/BF02818608; PMID: 9717250
   PubMed Web of Science ®Google Scholar
• Sansonetti PJ. The bacterial weaponry: lessons from Shigella. Ann N Y Acad Sci 2006; 1072:307 - 12; http://dx.doi.org/10.1196/annals.1326.025; PMID: 17057210
   PubMed Web of Science ®Google Scholar
• Egile C, Loisel TP, Laurent V, Li R, Pantaloni D, Sansonetti PJ, Carlier MF. Activation of the CDC42 effector N-WASP by the Shigella flexneri IcsA protein promotes actin nucleation by Arp2/3 complex and bacterial actin-based motility. J Cell Biol 1999; 146:1319 - 32; http://dx.doi.org/10.1083/jcb.146.6.1319; PMID: 10491394
   PubMed Web of Science ®Google Scholar
• Goldberg MB, Barzu O, Parsot C, Sansonetti PJ. Unipolar localization and ATPase activity of IcsA, a Shigella flexneri protein involved in intracellular movement. Infect Agents Dis 1993; 2:210 - 1; PMID: 8173795
   PubMedGoogle Scholar
• Goldberg MB, Theriot JA. Shigella flexneri surface protein IcsA is sufficient to direct actin-based motility. Proc Natl Acad Sci U S A 1995; 92:6572 - 6; http://dx.doi.org/10.1073/pnas.92.14.6572; PMID: 7604035
   PubMed Web of Science ®Google Scholar
• Lommel S, Benesch S, Rottner K, Franz T, Wehland J, Kühn R. Actin pedestal formation by enteropathogenic Escherichia coli and intracellular motility of Shigella flexneri are abolished in N-WASP-defective cells. EMBO Rep 2001; 2:850 - 7; http://dx.doi.org/10.1093/embo-reports/kve197; PMID: 11559594
   PubMed Web of Science ®Google Scholar
• Suzuki T, Miki H, Takenawa T, Sasakawa C. Neural Wiskott-Aldrich syndrome protein is implicated in the actin-based motility of Shigella flexneri. EMBO J 1998; 17:2767 - 76; http://dx.doi.org/10.1093/emboj/17.10.2767; PMID: 9582270
   PubMed Web of Science ®Google Scholar
• Gouin E, Welch MD, Cossart P. Actin-based motility of intracellular pathogens. Curr Opin Microbiol 2005; 8:35 - 45; http://dx.doi.org/10.1016/j.mib.2004.12.013; PMID: 15694855
   PubMed Web of Science ®Google Scholar
• Padrick SB, Rosen MK. Physical mechanisms of signal integration by WASP family proteins. Annu Rev Biochem 2010; 79:707 - 35; http://dx.doi.org/10.1146/annurev.biochem.77.060407.135452; PMID: 20533885
   PubMed Web of Science ®Google Scholar
• Torres E, Rosen MK. Contingent phosphorylation/dephosphorylation provides a mechanism of molecular memory in WASP. Mol Cell 2003; 11:1215 - 27; http://dx.doi.org/10.1016/S1097-2765(03)00139-4; PMID: 12769846
   PubMed Web of Science ®Google Scholar
• Torres E, Rosen MK. Protein-tyrosine kinase and GTPase signals cooperate to phosphorylate and activate Wiskott-Aldrich syndrome protein (WASP)/neuronal WASP. J Biol Chem 2006; 281:3513 - 20; http://dx.doi.org/10.1074/jbc.M509416200; PMID: 16293614
   PubMed Web of Science ®Google Scholar
• Cory GO, Garg R, Cramer R, Ridley AJ. Phosphorylation of tyrosine 291 enhances the ability of WASp to stimulate actin polymerization and filopodium formation. Wiskott-Aldrich Syndrome protein. J Biol Chem 2002; 277:45115 - 21; http://dx.doi.org/10.1074/jbc.M203346200; PMID: 12235133
   PubMed Web of Science ®Google Scholar
• Suetsugu S, Hattori M, Miki H, Tezuka T, Yamamoto T, Mikoshiba K, Takenawa T. Sustained activation of N-WASP through phosphorylation is essential for neurite extension. Dev Cell 2002; 3:645 - 58; http://dx.doi.org/10.1016/S1534-5807(02)00324-6; PMID: 12431372
   PubMed Web of Science ®Google Scholar
• Kim AS, Kakalis LT, Abdul-Manan N, Liu GA, Rosen MK. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 2000; 404:151 - 8; http://dx.doi.org/10.1038/35004513; PMID: 10724160
   PubMed Web of Science ®Google Scholar
• Cossart P. Actin-based motility of pathogens: the Arp2/3 complex is a central player. Cell Microbiol 2000; 2:195 - 205; http://dx.doi.org/10.1046/j.1462-5822.2000.00053.x; PMID: 11207576
   PubMed Web of Science ®Google Scholar
• Burton EA, Oliver TN, Pendergast AM. Abl kinases regulate actin comet tail elongation via an N-WASP-dependent pathway. Mol Cell Biol 2005; 25:8834 - 43; http://dx.doi.org/10.1128/MCB.25.20.8834-8843.2005; PMID: 16199863
   PubMed Web of Science ®Google Scholar
• Heindl JE, Saran I, Yi CR, Lesser CF, Goldberg MB. Requirement for formin-induced actin polymerization during spread of Shigella flexneri. Infect Immun 2010; 78:193 - 203; http://dx.doi.org/10.1128/IAI.00252-09; PMID: 19841078
   PubMed Web of Science ®Google Scholar
• Leung Y, Ally S, Goldberg MB. Bacterial actin assembly requires toca-1 to relieve N-wasp autoinhibition. Cell Host Microbe 2008; 3:39 - 47; http://dx.doi.org/10.1016/j.chom.2007.10.011; PMID: 18191793
   PubMed Web of Science ®Google Scholar
• Khan WN. Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase. Immunol Res 2001; 23:147 - 56; http://dx.doi.org/10.1385/IR:23:2-3:147; PMID: 11444380
   PubMed Web of Science ®Google Scholar
• Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010; 107:13075 - 80; http://dx.doi.org/10.1073/pnas.1004594107; PMID: 20615965
   PubMed Web of Science ®Google Scholar
• Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma 2013; http://dx.doi.org/10.3109/10428194.2013.777837; PMID: 23425038
   PubMed Web of Science ®Google Scholar
• Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31:88 - 94; http://dx.doi.org/10.1200/JCO.2012.42.7906; PMID: 23045577
   PubMed Web of Science ®Google Scholar
• Gu B, Ke X, Pan S, Cao Y, Zhuang L, Yu R, Qian H, Liu G, Tong M. Prevalence and trends of aminoglycoside resistance in Shigella worldwide, 1999-2010. J Biomed Res 2013; 27:103 - 15; http://dx.doi.org/10.7555/JBR.27.20120125; PMID: 23554801
   PubMedGoogle Scholar
• Kosek M, Yori PP, Olortegui MP. Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas. Curr Opin Infect Dis 2010; 23:475 - 80; http://dx.doi.org/10.1097/QCO.0b013e32833da204; PMID: 20689423
   PubMed Web of Science ®Google Scholar